Showing 3411-3420 of 4730 results for "".
- Fat Grafting Shows Promise for Cancer Patients with Radiation-induced Skin Injuryhttps://practicaldermatology.com/news/fat-grafting-shows-promise-for-cancer-patients-with-radiation-induced-skin-injury/2460730/As cancer survival rates improve, more people are living with the aftereffects of cancer treatment including chronic radiation-induced skin injury. Fat grafting procedures may unleash the healing and regenerative power of the body's natural adipose stem cells (ASCs). "Prelimina
- Sincerus Completes Financing With SWK To Support Demand For Customized Dermatologic Medicineshttps://practicaldermatology.com/news/sincerus-completes-financing-with-swk-to-support-demand-for-customized-dermatologic-medicines/2460727/Sincerus Pharmaceuticals, the parent company of Prescriber's Choice and Sincerus Florida, completed a major new round of growth financing with SWK Holdings Corporation, representing the largest investment into the company to date. Use of proceeds will include the build-out and expansion of a
- Study: Clear Masks Improve Communication with Patientshttps://practicaldermatology.com/news/study-clear-masks-improve-communication-with-patients/2460716/Seeing really is believing. New research shows that doctors who wear transparent face masks greatly improve communication with patients compared to doctors whose faces are blocked by a standard face masks. What’s more, providers who wore the ClearMask are also perc
- New from Solta: Meet the Next Generation Clear + Brilliant Laserhttps://practicaldermatology.com/news/new-from-solta-meet-the-next-generation-clear-brilliant-laser/2460711/Solta Medical is launching Clear + Brilliant Touch laser, the company’s next generation Clear + Brilliant laser. By seamlessly switching between two wavelengths with the Original and Perméa handpieces, physicians can now more easily deliver a
- Baricitinib Performs Well in Phase 3 AA Trialhttps://practicaldermatology.com/news/baricitinib-performs-well-in-phase-3-aa-trial/2460709/Eli Lilly and Company and Incyte’s Baricitinib is the first JAK inhibitor to demonstrate hair regrowth in a Phase 3 alopecia areata (AA) trial. Patients with severe alopecia areata who took baricitinib 2-mg or 4-mg once daily showed a statistically significant improvemen
- New Research Highlights Global Challenge of Leprosyhttps://practicaldermatology.com/news/new-research-highlights-global-challenge-of-leprosy/2460706/The global problem of leprosy may be bigger than recognized, new research suggests. In fact, 40 million individuals around the world require preventive treatment in order to reduce the incidence of leprosy or Hansen’s Disease by 90% in 22 years. The new research by
- Project IMPACT from VisualDX Aims to Reduce Disparities in Medicinehttps://practicaldermatology.com/news/project-impact-from-visualdx-aims-reduce-disparities-in-medicine/2460704/VisualDX is launching Project IMPACT (Improving Medicine’s Power to Address Care and Treatment), a global effort to reduce disparities in medicine and highlight ways to bridge gaps of knowledge and improve healthcare outcomes for patients of color. Inaugural members include thought leaders
- Galderma and Aklief Unveil "Me Being Me" Campaign, Survey Results on Acne Zoom Burdenhttps://practicaldermatology.com/news/galderma-and-aklief-unveil-me-being-me-campaign-survey-results-on-acne-zoom-burden/2460703/Galderma Laboratories, L.P. and Aklief (trifarotene) Cream, 0.005% are launching Me Being Me, a new consumer campaign that was crafted in response to today’s increasingly digital-focused world. The campaign is designed to inspire those living with acne to feel confident
- FDA Grants Priority Review of NDA for Incyte’s Ruxolitinib Cream for ADhttps://practicaldermatology.com/news/fda-grants-priority-review-of-nda-for-incytes-ruxolitinib-cream-for-ad/2460702/The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) of Incyte’s ruxolitinib cream for atopic dermatitis (AD) for priority review. The Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2021. Ruxolitinib cream is
- Five-Year Data for Ilumya Show Long-term Efficacy, Safetyhttps://practicaldermatology.com/news/five-year-data-for-ilumya-show-long-term-efficacy-safety/2460698/Long-term data from Phase 3 extension trials for Sun Pharma’s Ilumya (tildrakizumab) in psoriasis show the treatment provided sustained disease control over five years among subjects who were week 28 tildrakizumab responders and etanercept partial responders/nonresponders.